Proceeds from the Series C will be used to further fund the ongoing clinical trial of ImmunOs’ lead program IOS-1002 to completion of the Phase Ia dose escalation clinical trial as a monotherapy and ...

BURLINGTON, Mass. — MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, launched the first single-use reactor specifically designed to manufacture antibody ...

Merck’s cancer immunotherapy Keytruda is the drug industry’s biggest blockbuster, bringing in $25 billion in sales last year. For years drug companies have sought to beat the therapy to no avail.

It’s healthy to challenge yourself with new problems that create new pathways in the brain. While straightforward, puzzle games remain an invaluable source of brain stimulation. They push you to think ...

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

Merck faces significant challenges, including increased competition and regulatory scrutiny for Keytruda. Keytruda is facing potential threats from competitors like Summit Therapeutics ...

It is hard to get excited after looking at Merck's (NYSE:MRK) recent performance, when its stock has declined 5.6% over the past three months. But if you pay close attention, you might find that ...

The numbers listed above are not in base 10, also known as the decimal system. Show puzzle solution The terms of the sequence all represent the decimal (base 10) number 6 as it is represented in ...

“A good game is any game that people have decided that they really like,” explained Amanda Rafkin, a puzzle games expert and editor of the USA Today Crossword. If you like to play, there are ...

This children's puzzle is leaving even the brainiest of adults with a headache. No matter your age, you can get a lot out of puzzle games. Whether you love doing jigsaw puzzles or you're a fan of ...

A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer.